Signal active
Bio
Sean P. Nolan is an accomplished executive with over 24 years of pharmaceutical industry experience that includes leadership roles in building and creating significant value for both publicly held and private companies. He has a broad base of business experience in a multi-national pharmaceutical organization, M&A activities in a small, private equity backed company ($900MM) and in a public biotech company ($8.3B).He created, transformed, and optimized businesses through insightful leadership, strong execution skills, and deep business strategy and operational expertise. He is skilled at building compelling company, functional, and team visions and translating those visions into accomplishments.
Location
Chicago, Illinois, United States, North America
Social
Primary Organization
2013
11-50
Biotechnology, Health Care, Medical, Genetics
Jobs history
5
Encoded Therapeutics
Chairman
2018 - Current
Affinia Therapeutics
Chairman Of The Board
2019 - Current
InterMune
Executive Vice President and Chief Business Officer
2013 - Current
Taysha Gene Therapies
Board Member
2020 - Current
Encoded Therapeutics
Chairman
Invalid date - Current
Board and Advisor Roles
0
N/A
Invest in regions
Profile Resume
Sean P. Nolan is the President & Chief Executive Officer at AveXis, based in United States, North America. With a background in Biotechnology, Sean P. Nolan has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Investment portfolio
1
0
Personal investment
1
Annouced Date | Organization Name | Funding Round | Money Raised |
---|---|---|---|
Apr 13, 2021 | Jaguar Gene Therapy | Series B - Jaguar Gene Therapy | 139.0M |
Partner investment
2
Annouced Date | Organization Name | Funding Round | Investor Name | Money Raised |
---|---|---|---|---|
Apr 29, 2020 | Taysha Gene Therapies | Seed Round - Taysha Gene Therapies | Nolan Capital | 30.0M |
Aug 05, 2020 | Taysha Gene Therapies | Series B - Taysha Gene Therapies | Nolan Capital | 95.0M |
Exits
0
There is no exit available on this Profile
Invest in industries
Recent Activity
There is no recent news or activity for this profile.